Insulet’s OmniPod. Business Front.


Insulet’s OmniPod

Business Front: Insulet appears to be doing well on the business side these days. New patient starts were up 20% this past year, while new pediatric patients were up a full 30% over the previous year. So more patients are starting the OmniPod than ever before, it seems. Insulet CEO Pat Sullivan says the company now has a total 85,000 OmniPod users, as of the end of 2015. 

Insulet sold its Neighborhood Diabetes Business (the mail order medical supply company it acquired a few years ago) to Liberty Medical early this month, meaning those OmniPod customers who used Neighborhood Diabetes as a durable medical equipment provider will now be switched to Liberty.


Higher Concentrated-Insulin Pods: Insulet’s excited about its partnership with Eli Lilly for developing OmniPod devices that will have both the concentrated U-200 and U-500insulins inside. They’re queuing up a clinical study the U-500 version now, and already have a third of the required patients signed up. Insulet expects both of these new Pods to be available in the next 2 or 3 years, offering more choice for PWDs who may need more insulin.

Immune system could be used to regulate insulin in type 2 diabetes.

Immune system could be used to regulate insulin in type 2 diabetes.The immune system could help regulate insulin in type 2 diabetes, according to new research from Switzerland. Scientists from the University of Basel report that triggering immune cells located in the pancreas could help prevent insulin production from failing in people with type 2 diabetes.In a study of overweight people with type 2 diabetes, the researchers identified a feedback mechanism in the pancreas which had a positive influence on insulin secretion.The impact .

Dexcom CGM users to have clearer way of understanding trend arrows

A new method allows young people and adults with type 1 diabetes to better understand and make better use of trend arrow data from the Dexcom G5 mobile continuous glucose monitor (CGM) for adapting insulin doses.The Dexcom G5 CGM displays trend arrows indicating whether blood glucose levels are rising or falling, and how fast this is happening. Previously published methods on how best to use this data to adjust insulin doses were deemed imperfect and/or not user-friendly.Two recent studies, conducted by researchers from Harvard .

OmniPod DASH & Horizon

Insulet was showing off its DASH platform, which is basically a locked-down Android phone that will eventually replace the PDM (controller unit) for its tubeless insulin pump. “Locked down” means the phone will have no other regular cellular capabilities or other apps available, nor will it have an integrated fingerstick glucose meter like the current PDM. It also means that users will basically be carrying around two smartphones — a lot to schlep, possibly .

Insulin Pumps

 What They Do: Insulin pumps are devices that deliver insulin without the need for manual injections. They can administer both basal insulin and bolus (mealtime) insulin once users program the needed insulin dosing. Some new Medtronic systems can automatically suspend insulin dosing when glucose levels are low. Many pumps also come with built in bolus-calculators, which can reduce the hassle of manual insulin dose calculations. All pumps require the user to wear something directly on .

Insulet Presents Positive Omnipod® Horizon™ Hybrid Closed-Loop Study Results in Children

Insulet Presents Positive Omnipod® Horizon™ Hybrid Closed-Loop Study Results in Children
Strong results show potential for Horizon to improve clinical outcomes in pediatric and adolescent age groups with type 1 diabetes http://www.forbes.comJune 12, 2017 06:00 AM Eastern Daylight TimeBILLERICA, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced additional promising data from the first feasibility study of the Omnipod® Horizon™ Automated Glucose Control System (Omnipod Horizon) hybrid closed-loop system. Initial results presented earlier .

Omnipod & Dexcom Artificial Pancreas

  Omnipod & Dexcom Artificial Pancreas




Exciting news for users of the the Omnipod Insulin Pump and Dexcom CGM System. It looks like a Tubeless Artifical Pancreas may be on the horizon. Insulet the manufacturers of the Omnipod Tubeless Insulin Pump have just announced a partnership and licence agreement with Mode AGC (Automated Glucose Control LLC)  to develop an advanced artificial pancreas algorithm. The system will use the tubeless Omnipod pump and latest Dexcom technology.


I have to say this news is welcomed in our home. With the race now on for the worlds first artificial pancreas to make it into the pharmaceutical market, there are a number of projects currently underway. The idea of an artificial pancreas is of course appealing to many but my son has always claimed he didn’t want an artificial pancreas because he likes the pump he already has and doesn’t want to change. We use the Omnipod and have just started using the Dexcom G5 system, so we are delighted that there may be an artificial pancreas that utilizes the technology that we are already using.


One of the many battles that parents face with children diagnosed with Type 1 Diabetes is getting them to try new technology, it can be very scary for them. 



OmniPod Updates

Just this week, Insulet announced it had reached the milestone of 100,000 Podders, with a majority of those customers being young children and teens. Insulet’s own research reflects they now command 21% of the insulin pump market in the United States, sandwiched between Medtronic’s whopping 41% and competitors Animas and Tandem, each at 18%. This a big moment for the Boston-area company, which has been around sin
ce 2005 and, amazingly, remains the sole full-featured patch pump company here in the US.



Now, Insulet’s prepping for the launch of its next-generation product, that will bring the OmniPod into the mobile, data-sharing age.


New OmniPod DASH Platform – But No More Built-In Meter

During the company’s inuagral Investor Day on Nov. 16, they revealed some detail about their upcoming “DASH” platform (short for mobile dashboard, at your fingertips).The tubeless pod will retain the same form factor, but will have Bluetooth Low Energy wireless capability built in to allow for communication with a new color touchscreen PDM. This will also allow for communication with any BT-enabled fingerstick meter, but that means the next-gen OmniPod DASH won’t have a .

Insulet Reveals New Next Generation OmniPod Handheld

Twitter Summary: Updated OmniPod handheld brings touchscreen, Bluetooth, connection to Dexcom app. Likely available in 2016. At the 2015 ADA Scientific Sessions, Insulet revealed the prototype of its latest PDM handheld for the tubeless OmniPod insulin pump – a slimmer, color touchscreen display upgrade from its current model. The new PDM is a definite improvement, featuring a roughly 25% larger screen area, a rechargeable battery that lasts for four days, and Bluetooth capabilities to pair .